LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Summary Public Assessment Report

Diclofenac STADA
(diclofenac diethylamine)

SE/H/2588/01/MR

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

Summary Public Assessment Report

Diclofenac STADA
diclofenac diethylamine gel, 23.2 mg/g

This is a summary of the public assessment report (PAR) for Diclofenac STADA. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Diclofenac STADA and what is it used for?

The product is a 'hybrid medicine'. This means that it is similar to a reference medicine containing the same active substance.

The reference medicine for the product is Voltaren.

The company has provided additional own data to demonstrate therapeutic equivalence between the product and the reference medicine.

The product is intended only for cutaneous use to relieve mild to moderate pain in muscle and joint injuries (e.g. sports injuries).

How does Diclofenac STADA work?

The product belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Diclofenac has analgesic (pain-reducing), anti-inflammatory and antipyretic (fever-reducing) properties.

How is Diclofenac STADA used?

The pharmaceutical form is gel for topical administration.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Diclofenac STADA have been shown in studies?

Because the product is a hybrid application and is considered to be therapeutically equivalent to the reference product Voltaren, the benefits and risks are taken as being the same as those of the reference medicine.

What are the possible side effects from Diclofenac STADA?

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Diclofenac STADA approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Voltaren, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Diclofenac STADA?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Diclofenac STADA

The full PAR for Diclofenac STADA can be found on the following website: http://mri.medagencies.org/Human/. For more information about treatment with Diclofenac STADA, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2024-11.